clinical trial · NCT07753993
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Chronic Kidney DiseaseElecoglipronPlacebo
brief summary
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
started
Aug 28, 2026
primary completion
Oct 4, 2030
completion
Oct 4, 2030
last updated
Aug 10, 2026
official title
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol